Clinical Trial Update: A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Ceftazidime-Avibactam to Meropenem in hospitalized adults with nosocomial pneumonia (including VAP) completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nosocomial Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Meropenem (Meropenem)
• ceftazidime/avibactam (ceftazidime/avibactam)

Snippet

Sponsor: Pfizer | Conditions: Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP) | Phase 3 | Status: COMPLETED | Results posted: 2017-02-03